**Name of Journal:** *World Journal of* *Gastroenterology*

**ESPS Manuscript NO: 18156**

**Manuscript Ty**pe: **TOPIC HIGHLIGHT**

**2015 Advances in Inflammatory Bowel Disease**

**Promises and paradoxes of regulatory T cells in inflammatory bowel disease**

Lord JD. Regulatory T Cells in IBD

James D Lord

**James D Lord,** Translational Program Benaroya Research Institute at Virginia Mason Mailstop, Seattle, WA 98101, United States

**Author contributions:** Lord JD performed all literature review and writing associated with this manuscript.

**Conflict-of-interest statement:** James D Lord has received research funding from Novo Nordisk, Zymogenetics and Janssen Pharmaceuticals.

**Open-Access:** This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers.It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **James D Lord, MD, PhD,** Research Assistant Member, Translational Program Benaroya Research Institute at Virginia Mason Mailstop IN-RC 1201 Ninth Avenue, Seattle, WA 98101, United States. james.lord@vmmc.org

**Telephone: +**1-98-1012795

**Fax: +**1-98-1012795

**Received:** April 9, 2015

**Peer-review started:** April 9, 2015

**First decision:** May 18, 2015

**Revised:** June 2, 2015

**Accepted:** August 28, 2015

**Article in press:**

**Published online:**

**Abstract**

Since their discovery two decades ago, CD4+CD25+Foxp3+ regulatory T cells (Tregs) have become the subject of intense investigation by immunologists. Unlike other T cells, which promote an immune response, Tregs actively inhibit inflammation when activated by their cognate antigen, thus raising hope that these cells could be engineered into a highly targeted, antigen-specific, immunosuppressant therapy. Although Tregs represent less than 10% of circulating CD4+T cells, they have been shown to play an essential role in preventing or limiting inflammation in a variety of animal models and human diseases. In particular, spontaneous intestinal inflammation has been shown to occur in the absence of Tregs, suggesting that there may be a Treg defect central to the pathogenesis of human inflammatory bowel disease (IBD). However, over the past decade, multiple groups have reported no qualitative or quantitative deficits in Tregs from the intestines and blood of IBD patients to explain why these cells fail to regulate inflammation in Crohn’s disease and ulcerative colitis. In this review, we will discuss the history of Tregs, what is known about them in IBD, and what progress and obstacles have been seen with efforts to employ them for therapeutic benefit.

**Key words**: Foxp3; Regulatory T cells; Crohn’s disease; Th17; Ulcerative colitis; Inflammatory bowel disease

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Regulatory T cells (Tregs) have received much interest in animal models of inflammatory bowel disease (IBD), but have yet to demonstrate a clear defect in human Crohn’s disease or ulcerative colitis. This review will detail our current knowledge about this important regulatory arm of the immune system in human IBD, and discuss the potential role for Tregs as immunotherapy.

Lord JD. Promises and paradoxes of regulatory T cells in inflammatory bowel disease. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

In the summer of 1995, Shimon Sakaguchi published the first report of what later came to be recognized as regulatory T cells (Tregs) by demonstrating that mice depleted of CD4+CD25+ T cells spontaneously developed multiorgan autoimmunity, including gastrointestinal (GI) inflammation[1]. More importantly, such autoimmunity could be prevented by administration of these CD4+CD25+ Tregs, suggesting that they might someday represent a potent cellular therapy for autoimmune and chronic inflammatory conditions. In the twenty years since this initial report, well over 10000 original manuscripts have been published concerning Tregs, making them one of the most intensely studied T cell populations of the 21st century.

Interest in Tregs took a quantum leap forward shortly after the turn of the millennium, when it was discovered that the gene FOXP3 was central to Treg development and function, and could serve as an excellent marker for these relatively rare cells. A genetic defect in the *FOXP3* gene which precluded Treg development was found to be the cause of a mouse multiorgan inflammatory condition called scurfy[2]. At roughly the same time, a similar human condition called immune polyendocrinopathy enteropathy X-linked (IPEX) was reported to result from mutations in the human FOXP3 gene resulting in humans with no Tregs[3,4]. As the name implies, an inflammatory enteropathy, resembling severe pan-intestinal Crohn’s disease, is a central feature of IPEX, and generally causes fatal malnutrition in the absence of a hematopoietic cell transplant (HCT).This condition made it clear that the Tregs which had been receiving increasing attention in murine models were also critical for intestinal immune homeostasis in humans.

**TREG MECHANISMAS OF ACTION**

We now know that FOXP3+ Tregs reside within the intestinal lamina propria and represent up to 10% of circulating CD4+ T cells in humans[5-8]. Tregs recognize specific MHC-II-bound peptide antigens though a clonally unique T cell receptor (TCR), just like any other CD4+ T cells[7,9]. However, while other T cells will deliver pro-inflammatory signals upon TCR ligation, Tregs do the opposite. They inhibit the activation of bystander T cells in a contact-dependent manner[10]. While no single molecular mechanism for this inhibition has been elucidated, several regulatory signals appear to be important (Figure 1), augmentation of which would represent an attractive opportunity for IBD therapy.

By definition, Tregs express more CD25 than any other T cells[1], and because CD25 is an essential component of the high-affinity IL-2 receptor, Tregs may absorb local IL-2, depriving nearby T cells of this T cell growth and survival factor when its concentration is limiting. However, IL-2 is evidently not essential for pro-inflammatory T cell growth and survival because mice genetically engineered to lack CD25[11] or the beta chain of the IL-2 receptor (CD122)[12] do not develop immunodeficiency, but rather a lymphoproliferative disorder including spontaneous autoimmunity and IBD. This was evidently due to a lack of Tregs[13], as the latter are uniquely dependent upon IL-2. Thus, depriving other T cells of IL-2 is certainly not central to the inhibitory effect of Tregs *in vivo*.

Tregs also constitutively express more of the immunoregulatory CTLA4 molecule (CD152) than other T cells[8,14,15], and this molecule appears to be necessary for Treg inhibitory function[15,16]. CTLA4 can bind up B7-1 (CD80) and B7-2 (CD86) costimulatory molecules on the surface of antigen presenting cells (APC), preventing them from costimulating CD28 receptors on other T cells[17]. Mice lacking the CTLA4 gene develop multiorgan autoimmunity[18] not unlike mice lacking Tregs. Similarly, patients who receive the CTLA4-blocking antibody ipilimumab as a cancer immunotherapy can develop spontaneous autoimmunity, including enterocolitis in over 20% of recipients[19,20], thus demonstrating the importance of this molecule in maintaining intestinal immune homeostasis. However, whether CTLA4’s role is primarily mediated through Tregs is unclear, as ipilimumab also limits CTLA4 engagement on activated T cells.

TIGIT, a molecule analogous to CTLA4, is also enriched on a subset of Tregs[21,22], and likewise binds costimulatory molecules (CD112, CD155) on APC, preventing them from ligating a costimulatory receptor (CD226) on effector T cells, and thereby inhibiting the latter[23]. TIGIT+ Tregs have been reported to selectively inhibit Th1 and Th17 cells, the CD4+ T cell populations commonly associated with autoimmune and inflammatory conditions like IBD[24]. Tregs also express PD-1 (CD279)[25], an inhibitory receptor that interacts with PD-L1 (CD274) and PD-L2 (B7-DC, CD273) on APCs and has, like CTLA4, recently become a target for cancer immunotherapy[26-29]. Like CTLA4 blockade, PD-1 blockade has caused spontaneous intestinal inflammation in clinical trials, albeit at a lower rate, affecting <10% of recipients[30,31].

In addition to their contact-dependent immunomodulatory mechanisms, Tregs may control inflammation through soluble factors. CD39 is an ectonucleotidase preferentially expressed by Tregs, which hydrolizes ATP and ADP to AMP, and ultimately adenosine[32,33]. ATP has been reported to enhance pro-inflammatory Th17 cells[34,35], while adenosine may inhibit effector T cells through the A2A receptor[36-39], so this surface receptor may change the local environment of the Tregs to regulate inflammation. Reduced Treg expression of CD39 has been described in lupus[40] and multiple sclerosis[32,32,41], but has not yet been described in IBD.

Tregs have also been reported to control inflammation through cytokines. TGF-β is expressed by Tregs, and has immunomodulatory properties, although it may function as a cell-surface protein on Tregs[42], and may not be necessary for Treg inhibitory function[43]. IL-10 is likewise an immunomodulatory cytokine made by Tregs[42], and is essential for preventing spontaneous bowel inflammation in mice[44] and humans[45]. However, the immunoregulatory roles of IL-10 and TGF-β may be more appropriately ascribed to other “regulatory T cell” populations that do not express FOXP3, namely Tr1[46,47] and Th3 cells[48], which are beyond the scope of this review. More recently, FOXP3+ Tregs have been shown to mediate their inhibitory function through the cytokine IL-35[49,50].

**TREGS IN IBD**

A number of clinical observations and experiments in animal models[51,52] have suggested that Tregs or their inhibitory mechanisms are critical for preventing spontaneous intestinal inflammation, and thus suggested that a defect in Tregs may be central to the pathogenesis of UC and/or Crohn’s disease. Out of 38 distinct animal models of IBD reviewed in 2003, nine involved Tregs or their inhibitory mechanisms[51,53]. As an iatrogenic inflammatory bowel disease, human gastrointestinal graft *vs* host disease (GVHD) following HCT has been associated with evidence of decreased Tregs in the blood[54] and intestinal mucosa[55].

Despite this wealth of data implicating Tregs in intestinal immune homeostasis, direct evaluation of Tregs in the intestines of IBD patients has not identified obvious defects. The first report of CD4+CD25+ Tregs isolated from the intestinal lamina propria (LP) of IBD patients, published more than a decade ago, demonstrated that these cells are present, express CTLA4, and show *in vitro* suppressive activity against other T cells which is no different from those of controls[56]. This and subsequent reports found that these Tregs paradoxically represent a greater fraction of LP CD4+ T cells in the intestines of IBD patients than healthy control subjects[5] and are no less common in bowel affected by IBD than in bowel inflamed for other reasons, such as infection[51]. Paradoxically, Tregs are even more common in actively inflamed than uninflamed IBD mucosa[5,57-59], with a reciprocal drop in circulating Treg frequency in the peripheral blood of symptomatic IBD patients likely reflecting sequestration of these cells to the site of inflammation. Thus, the mucosal inflammation of IBD appears to be different from that of IPEX in that it does not result from any local dearth of FOXP3+ cells.

**ACTIVATION INDUCED FOXP3 EXPRESSION**

Confounding these analyses was the discovery that FOXP3 expression could be induced *de novo* in human T cells that were originally FOXP3 negative by TCR activation in the presence of TGF-β[60,61]. Thus the seemingly paradoxical excess of FOXP3+ cells in the inflamed mucosa of an IBD patient could simply be locally activated T cells. Complicating matters, by some accounts, T cells induced to express FOXP3 by activation are nonetheless effective regulators of other immune cells *in vitro*[62,63]. Whether these “induced Tregs” (iTregs) have all the same suppressive function *in vivo* as constitutively FOXP3+ “natural” Tregs (nTregs) has been debated[64], and is difficult to establish experimentally in humans. One significant difference between iTregs and nTregs concerns their ability to make cytokines. Classical nTregs do not make pro-inflammatory cytokines, such as IL-2 or IFN-γ, and additionally show demethylation of CpG sites in the FOXP3 promoter[6]. In contrast, iTregs generated from effector T cells retain their ability to produce these cytokines[64], and do not demethylate their FOXP3 promoter[65], although they do up-regulate CD25 and CTLA4 to resemble nTregs[64], making it difficult to discern the two Treg populations by surface markers. Adding to the complexity, it has become clear that the “nTregs” that constitutively express FOXP3 *in vivo* are actually a mix of Tregs that either acquired FOXP3 expression in the thymus (tTregs) or periphery (pTregs), thus reflecting their antigen specificity and perhaps phenotype[66].

The nuclear protein Helios has been shown to be constitutively expressed by thymically-derived tTregs, but not *in vitro*-generated iTregs[67], making this a potentially unique marker with which to distinguish at least these two populations. The fraction of FOXP3+ LP T cells that express Helios is no lower in IBD patients than controls[68], suggesting that the paradoxically increased FOXP3+ T cells in IBD are not exclusively iTregs. However, there is evidence that activation-induced FOXP3+ T cells may acquire Helios expression[69], thus compromising the reliability of Helios as a marker for distinguishing iTregs from nTregs.

The TCR gene is uniquely rearranged in each nascent T cell, making it a stable genetic marker with which to identify T cells from a common clonal origin. By comparing the TCR V hypervariable domain repertoires of FOXP3+ and FOXP3- T cell populations from the colon LP, it has been shown that these are predominantly distinct populations, even in IBD[68]. Indeed, LP Helios－ Tregs show no more similarity in their TCR repertoire to effector T cells than they do to Helios+ Tregs[68]. Thus, the paradoxically increased mucosal FOXP3+ cells in IBD cannot be explained solely by activation-induced FOXP3 expression among effector T cells.

**TREG *VS* TH17 CELLS**

Several groups have noted that an unusually high fraction of mucosal Tregs from IBD patients are able to produce IL-17A[70-72]. IL-17A is a potent pro-inflammatory cytokine associated with neutrophil recruitment[73], and hence thought to play a central role in anti-bacterial immune responses. It is made by a subset of effector T cells, called Th17 cells, which can be identified by CCR6[74] and CD161 expression[75], and have been implicated in multiple autoimmune conditions[76]. Thus, by sharing characteristics with a potentially pathogenic class of T cells, the copious intestinal FOXP3+ Tregs present in IBD could paradoxically promote rather than suppress intestinal inflammation.

Like iTregs, Th17 cells require TGF-β for their development, but additionally require IL-6, which in turn suppresses the formation of FOXP3+ Tregs[77,78]. The differentiation of Th17 cells is governed by the transcription factor RORt[74,79] instead of FOXP3. In cells that express both transcription factors, FOXP3 physically interacts with RORt in the nucleus to prevent the latter from promoting IL-17A expression[80]. This interaction requires a region of the FOXP3 protein encoded by exon 2 of the FOXP3 mRNA[80], which is deleted in a splice variant (exon 2) that represents approximately half the FOXP3 transcripts expressed by humans[81]. This would suggest that IL-17-producing FOXP3+ T cells, as seen in IBD, could be exclusively expressing the exon 2 variant of FOXP3. However, no predominance of exon 2 relative to full-length FOXP3 expression is seen in IBD, nor are there cells which exclusively express exon 2, even among IL-17-expressing FOXP3+ T cells[57]. Thus, how Th17-like FOXP3+ T cells arise in IBD remains a mystery, but could be due to an increased responsiveness to IL-6, as has been seen in T cells from multiple sclerosis patients[82].

**TREG AND THE INTESTINAL FLORA**

With the recent advent of inexpensive, high-throughput nucleic acid sequencing techniques, the bacterial flora, or “microbiome”, of the GI tract has recently come under intense scrutiny. Differences between the intestinal microbiomes of people with and without IBD have been described by many independent researchers[83-86], although it is difficult to determine whether such differences are a cause or effect of IBD once sufficient inflammation has occurred in the GI tract to diagnose an individual with IBD. Nonetheless, a leading hypothesis about the pathogenesis of IBD dictates that the immune system is losing tolerance to intestinal commensal flora, suggesting a dominant role for the microbiome.

Studies in germ-free mice have demonstrated that the gut microbiome is important for development of the normal intestinal immune system, as reviewed elsewhere[87]. This includes IL-10-producing, peripherally-induced FOXP3+ Tregs, whose development can be driven by specific intestinal microbiota in animal models[88,89]. While some intestinal Treg development may simply be due to exposure to luminal peptide antigens, non-peptide bacterial products, such as short-chain fatty acids[90] or specific polysaccharides[88], are important for Treg induction in the gut. Likewise, ingested micronutrients, such as retinoic acid, have been shown to contribute to the peripheral generation of FOXP3+ Tregs in the gut[91]. Thus, exposure of the intestinal mucosa to the fecal stream may be an important means by which the mucosal immune system develops tolerance, or perhaps fails to do so in IBD.

**TREG IN IBD THERAPY**

Contemporaneous with the growth of research on Tregs in the early 21st century was the use of biopharmaceutical therapy for IBD and other inflammatory conditions involving TNF- blockade. Perhaps as a consequence, a number of groups analyzed the effect of anti-TNF agents, particularly infliximab, on circulating FOXP3+ Tregs, and found that the latter were enriched in the peripheral blood of patients demonstrating a good clinical response to therapy[92-95]. This suggests that the blockade of TNF-*in vivo* may enhance Treg development, expansion, or viability if this cytokine normally inhibits Tregs in the setting of inflammation. Alternatively, because anti-TNF drugs can cause apoptosis of TNF-producing cells, and Tregs do not make TNF-, it is possible this effect reflects a selective “pruning” of the FOXP3- effector T cell population rather than expansion of FOXP3+ Tregs. However, caution should be taken in drawing conclusions about IBD from peripheral blood analyses, as the intestinal lamina propria houses more lymphocytes than the circulation. Thus selective sequestration or release of cell populations to or from the gut can actually cause the blood to reflect the opposite of what is actually happening at the site of inflammation in IBD. Indeed, the effect of anti-TNF agents on intramucosal Tregs has been less clear, with some researchers reporting a drop in FOXP3+ cells on therapy[94], and others reporting an increase[95]. Further confounding these analyses is the observation that histological IBD activity correlates inversely with Treg frequency in tissue sections[5,57-59], such that a drop in tissue Tregs in the setting of effective therapy could obscure any local enrichment, and if mediated by a release of Tregs into circulation, produce the observed increase in blood Tregs.

The effect of other immunosuppressive therapies on Tregs has been less intensely studied in IBD, but data exists from other conditions for which these drugs are used. In liver transplant recipients, use of the immunosuppressive drug azathioprine has been paradoxically associated with decreased colonic FOXP3+ cells, although only as cotherapy with prednisone and calcineurin inhibitors[96]. Likewise, in autoimmune hepatitis, azathioprine use, again in conjunction with prednisone, resulted in decreased intrahepatic Tregs, although a higher ratio of these Tregs to other lymphocytes correlated with biochemical remission[97]. Although these effects could be attributed to cotherapy with prednisone, studies in asthmatics have shown no effect of oral glucocorticoids on circulating Treg frequency[97]. Furthermore, as with anti-TNF agents, it is difficult to demonstrate that changes in Tregs associated with a given therapy represent a cause or effect of changes in inflammatory activity. Whether the newer anti-integrin biopharmaceutical vedolizumab will have an effect on intramucosal Tregs has yet to be seen, but a similar agent, natalizumab, did not alter the ratio of Tregs to other T cells in the intestinal mucosa of Crohn’s patients receiving it[98].

**TREGS AS IBD THERAPY**

Shortly after their discovery, Tregs were proposed as a potential therapy for autoimmune or inflammatory disease in more reviews and editorials than can be listed here. Indeed, in many animal models, adoptive transfer of Tregs proved effective for the prevention or treatment of inflammatory conditions, including IBD[99]. However, more than a decade later, the application of Tregs to human disease has been surprisingly limited. Given their rarity in peripheral blood, a major obstacle to therapeutic application of Tregs has been simply having enough Tregs to administer, so much work went into expanding or generating Tregs *in vitro* into a large, stable population with stable suppressive function. The earliest and most extensive efforts applying Tregs as anti-inflammatory therapy have been directed at GVHD complicating HCT[100-102], a condition which, like IBD, commonly involves deregulated intestinal inflammation. As an alternative to adoptive transfer of *in vitro* expanded Tregs, *in vivo* expansion of Tregs post HCT through the use of low-dose IL-2 has demonstrated efficacy against GVHD[103-105]. Low dose IL-2 also expanded Tregs in type-I diabetes[106,107], but it paradoxically accelerated autoimmunity, even when given with the immunosuppressant rapamycin, perhaps because it also expanded eosinophils and NK cells[107]. However, some efficacy has been seen with adoptive transfer of Tregs in type-I diabetes[108,109].

The first trial of adoptive transfer of Tregs as a therapy for IBD was recently published as an 8-week, open-label, dose-ranging study involving 20 Crohn’s patients[110]. In contrast to the aforementioned trials in GVHD and diabetes, the transferred Tregs were selected and cloned to be specific for a dietary antigen (chicken egg ovalbumin) so that antigen-specific activation of the transferred cells could be stimulated in the gastrointestinal tract through an egg-intensive diet (meringue cake). 40% of recipients demonstrated clinical improvement, although the most improvement was paradoxically seen in recipients of the smallest number of Tregs (106), and only minimal improvement was observed by objective measures of inflammation, such as C reactive protein and fecal calprotectin. Thus, the efficacy of Tregs as IBD therapy was neither straightforward nor overwhelming, suggesting that other factors, such as Treg antigen specificity or inhibitory function, may be more important than Treg numbers. Curiously, the number of circulating FOXP3+ T cells decreased in responders, while rising in non-responders. However, the frequency of Tregs in the intestines was not evaluated, so this dichotomy could reflect mucosal Treg sequestration if such a phenomenon was associated with therapeutic response.

**CONCLUSION**

Despite extensive interest in Tregs as central mediators of intestinal immune homeostasis, there is surprisingly little evidence that a defect in Tregs is associated with either form of human IBD. The fact that inflammation persists in Crohn’s and UC despite an excess of Tregs in the mucosa relative to healthy bowel indicates that the inflammation of IBD is resistant to their presence. Whether the mucosal Tregs of IBD patients are intrinsically defective in their ability to regulate mucosal inflammation *in vivo* is unknown, but *in vitro* assays have shown no such functional defect[56,58,59]. Alternatively, Treg-extrinsic factors could undermine the immunoregulatory function of Tregs. Other immune cells, such as FOXP3-negative effector T cells, could be resistant to the inhibitory function of Tregs in IBD, as has been described in multiple sclerosis and diabetes[82,111]. Mucosal dendritic and other antigen presenting cells with which Tregs and other T cells interact could deliver signals which undermine Treg-mediated inhibition. Finally, the mucosal microenvironment in general, including soluble factors and components of the extracellular matrix, such as hyaluronic acid[112], could be actively detrimental to, or passively unsupportive of, the inhibitory function of Tregs in IBD. A better understanding of the factors that undermine Treg function in IBD will be necessary before the promise of Tregs as an IBD therapy can ultimately be realized.

**REFERENCES**

1 **Sakaguchi S**, Sakaguchi N, Asano M, Itoh M, Toda M.Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J.Immunol.1995.*J Immunol* 2011; **186**: 3808-3821 [PMID: 21422251]

2 **Brunkow ME**, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F.Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse.*Nat Genet* 2001; **27**: 68-73 [PMID: 11138001 DOI: 10.1038/83784]

3 **Bennett CL**, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD.The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.*Nat Genet* 2001; **27**: 20-21 [PMID: 11137993 DOI: 10.1038/83713]

4 **Wildin RS**, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME.X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.*Nat Genet* 2001; **27**: 18-20 [PMID: 11137992 DOI: 10.1038/83707]

5 **Maul J**, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R.Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.*Gastroenterology* 2005; **128**: 1868-1878 [PMID: 15940622 DOI: 10.1053/j.gastro.2005.03.043]

6 **Miyara M**, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S.Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.*Immunity* 2009; **30**: 899-911 [PMID: 19464196 DOI: 10.1016/j.immuni.2009.03.019]

7 **Baecher-Allan C**, Brown JA, Freeman GJ, Hafler DA.CD4+CD25high regulatory cells in human peripheral blood.*J Immunol* 2001; **167**: 1245-1253 [PMID: 11466340 DOI: 10.4049/jimmunol.167.3.1245]

8 **Dieckmann D**, Plottner H, Berchtold S, Berger T, Schuler G.Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.*J Exp Med* 2001; **193**: 1303-1310 [PMID: 11390437 DOI: 10.1084/jem.193.11.1303]

9 **Suri-Payer E**, Amar AZ, Thornton AM, Shevach EM.CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.*J Immunol* 1998; **160**: 1212-1218 [PMID: 9570536]

10 **Thornton AM**, Shevach EM.CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.*J Exp Med* 1998; **188**: 287-296 [PMID: 9670041 DOI: 10.1084/jem.188.2.287]

11 **Willerford DM**, Chen J, Ferry JA, Davidson L, Ma A, Alt FW.Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.*Immunity* 1995; **3**: 521-530 [PMID: 7584142 DOI: 10.1016/1074-7613(95)90180-9]

12 **Suzuki H**, Kündig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H.Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta.*Science* 1995; **268**: 1472-1476 [PMID: 7770771 DOI: 10.1126/science.7770771]

13 **Malek TR**, Yu A, Vincek V, Scibelli P, Kong L.CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice.Implications for the nonredundant function of IL-2.*Immunity* 2002; **17**: 167-178 [PMID: 12196288 DOI: 10.1016/S1074-7613(02)00367-9]

14 **Jonuleit H**, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH.Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.*J Exp Med* 2001; **193**: 1285-1294 [PMID: 11390435 DOI: 10.1084/jem.193.11.1285]

15 **Takahashi T**, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S.Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.*J Exp Med* 2000; **192**: 303-310 [PMID: 10899917 DOI: 10.1084/jem.192.2.303]

16 **Read S**, Malmström V, Powrie F.Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.*J Exp Med* 2000; **192**: 295-302 [PMID: 10899916 DOI: 10.1084/jem.192.2.295]

17 **Teft WA**, Kirchhof MG, Madrenas J.A molecular perspective of CTLA-4 function.*Annu Rev Immunol* 2006; **24**: 65-97 [PMID: 16551244 DOI: 10.1146/annurev.immunol.24.021605.090535]

18 **Waterhouse P**, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW.Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.*Science* 1995; **270**: 985-988 [PMID: 7481803 DOI: 10.1126/science.270.5238.985]

19 **Beck KE**, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.*J Clin Oncol* 2006; **24**: 2283-2289 [PMID: 16710025]

20 **Lord JD**, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB.Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.*Dig Dis Sci* 2010; **55**: 1396-1405 [PMID: 19507029 DOI: 10.1007/s10620-009-0839-8]

21 **Zhang Y**, Maksimovic J, Naselli G, Qian J, Chopin M, Blewitt ME, Oshlack A, Harrison LC.Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells.*Blood* 2013; **122**: 2823-2836 [PMID: 23974203 DOI: 10.1182/blood-2013-02-481788]

22 **Bin Dhuban K**, d'Hennezel E, Nashi E, Bar-Or A, Rieder S, Shevach EM, Nagata S, Piccirillo CA.Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells.*J Immunol* 2015; **194**: 3687-3696 [PMID: 25762785 DOI: 10.4049/jimmunol.1401803]

23 **Levin SD**, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, Johnston J, Hammond A, Bontadelli K, Ardourel D, Hebb L, Wolf A, Bukowski TR, Rixon MW, Kuijper JL, Ostrander CD, West JW, Bilsborough J, Fox B, Gao Z, Xu W, Ramsdell F, Blazar BR, Lewis KE.Vstm3 is a member of the CD28 family and an important modulator of T-cell function.*Eur J Immunol* 2011; **41**: 902-915 [PMID: 21416464 DOI: 10.1002/eji.201041136]

24 **Joller N**, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, Sharpe AH, Quintana FJ, Mathis D, Benoist C, Hafler DA, Kuchroo VK.Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.*Immunity* 2014; **40**: 569-581 [PMID: 24745333 DOI: 10.1016/j.immuni.2014.02.012]

25 **Raimondi G**, Shufesky WJ, Tokita D, Morelli AE, Thomson AW.Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells.*J Immunol* 2006; **176**: 2808-2816 [PMID: 16493037 DOI: 10.4049/jimmunol.176.5.2808]

26 **Weber JS**, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.Nivolumab *vs* chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.*Lancet Oncol* 2015; **16**: 375-384 [PMID: 25795410 DOI: 10.1016/S1470-2045(15)70076-8]

27 **Robert C**, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.Nivolumab in previously untreated melanoma without BRAF mutation.*N Engl J Med* 2015; **372**: 320-330 [PMID: 25399552 DOI: 10.1056/NEJMoa1412082]

28 **Armand P**, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.*J Clin Oncol* 2013; **31**: 4199-4206 [PMID: 24127452 DOI: 10.1200/JCO.2012.48.3685]

29 **Hamid O**, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.*N Engl J Med* 2013; **369**: 134-144 [PMID: 23724846 DOI: 10.1056/NEJMoa1305133]

30 **Gibney GT**, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.*Clin Cancer Res* 2015; **21**: 712-720 [PMID: 25524312 DOI: 10.1158/1078-0432.CCR-14-2468]

31 **Brahmer JR**, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.*J Clin Oncol* 2010; **28**: 3167-3175 [PMID: 20516446 DOI: 10.1200/JCO.2009.26.7609]

32 **Borsellino G**, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K.Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.*Blood* 2007; **110**: 1225-1232 [PMID: 17449799 DOI: 10.1182/blood-2006-12-064527]

33 **Deaglio S**, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC.Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.*J Exp Med* 2007; **204**: 1257-1265 [PMID: 17502665 DOI: 10.1084/jem.20062512]

34 **Killeen ME**, Ferris L, Kupetsky EA, Falo L, Mathers AR.Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.*J Immunol* 2013; **190**: 4324-4336 [PMID: 23479230 DOI: 10.4049/jimmunol.1202045]

35 **Paustian C**, Taylor P, Johnson T, Xu M, Ramirez N, Rosenthal KS, Shu S, Cohen PA, Czerniecki BJ, Koski GK.Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17.*PLoS One* 2013; **8**: e54804 [PMID: 23382974 DOI: 10.1371/journal.pone.0054804]

36 **Ohta A**, Sitkovsky M.Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.*Nature* 2001; **414**: 916-920 [PMID: 11780065 DOI: 10.1038/414916a]

37 **Lappas CM**, Rieger JM, Linden J.A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells.*J Immunol* 2005; **174**: 1073-1080 [PMID: 15634932 DOI: 10.4049/jimmunol.174.2.1073]

38 **Ohta A**, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M.A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.*J Immunol* 2009; **183**: 5487-5493 [PMID: 19843934 DOI: 10.4049/jimmunol.0901247]

39 **Linden J**, Cekic C.Regulation of lymphocyte function by adenosine.*Arterioscler Thromb Vasc Biol* 2012; **32**: 2097-2103 [PMID: 22772752 DOI: 10.1161/ATVBAHA.111.226837]

40 **Loza MJ**, Anderson AS, O'Rourke KS, Wood J, Khan IU.T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.*Cell Immunol* 2011; **271**: 110-117 [PMID: 21763644 DOI: 10.1016/j.cellimm.2011.06.010]

41 **Fletcher JM**, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy N, Mills KH.CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.*J Immunol* 2009; **183**: 7602-7610 [PMID: 19917691 DOI: 10.4049/jimmunol.0901881]

42 **Nakamura K**, Kitani A, Strober W.Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.*J Exp Med* 2001; **194**: 629-644 [PMID: 11535631 DOI: 10.1084/jem.194.5.629]

43 **Piccirillo CA**, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, Shevach EM.CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.*J Exp Med* 2002; **196**: 237-246 [PMID: 12119348 DOI: 10.1084/jem.20020590]

44 **Kühn R**, Löhler J, Rennick D, Rajewsky K, Müller W.Interleukin-10-deficient mice develop chronic enterocolitis.*Cell* 1993; **75**: 263-274 [PMID: 8402911 DOI: 10.1016/0092-8674(93)80068-P]

45 **Glocker EO**, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C.Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.*N Engl J Med* 2009; **361**: 2033-2045 [PMID: 19890111 DOI: 10.1056/NEJMoa0907206]

46 **Levings MK**, Roncarolo MG.T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties.*J Allergy Clin Immunol* 2000; **106**: S109-S112 [PMID: 10887343 DOI: 10.1067/mai.2000.106635]

47 **Asseman C**, Powrie F.Interleukin 10 is a growth factor for a population of regulatory T cells.*Gut* 1998; **42**: 157-158 [PMID: 9536936 DOI: 10.1136/gut.42.2.157]

48 **Fukaura H**, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA.Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.*J Clin Invest* 1996; **98**: 70-77 [PMID: 8690806 DOI: 10.1172/JCI118779]

49 **Collison LW**, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA.The inhibitory cytokine IL-35 contributes to regulatory T-cell function.*Nature* 2007; **450**: 566-569 [PMID: 18033300 DOI: 10.1038/nature06306]

50 **Collison LW**, Pillai MR, Chaturvedi V, Vignali DA.Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner.*J Immunol* 2009; **182**: 6121-6128 [PMID: 19414764 DOI: 10.4049/jimmunol.0803646]

51 **Uhlig HH**, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F.Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis.*J Immunol* 2006; **177**: 5852-5860 [PMID: 17056509 DOI: 10.4049/jimmunol.177.9.5852]

52 **Gad M**.Regulatory T cells in experimental colitis.*Curr Top Microbiol Immunol* 2005; **293**: 179-208 [PMID: 15981481DOI: 10.1007/3-540-27702-1\_9]

53 **Mizoguchi A**, Mizoguchi E, Bhan AK.Immune networks in animal models of inflammatory bowel disease.*Inflamm Bowel Dis* 2003; **9**: 246-259 [PMID: 12902848 DOI: 10.1097/00054725-200307000-00005]

54 **Miura Y**, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD.Association of Foxp3 regulatory gene expression with graft-*vs*-host disease.*Blood* 2004; **104**: 2187-2193 [PMID: 15172973 DOI: 10.1182/blood-2004-03-1040]

55 **Rieger K**, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, Bornhäuser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L.Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.*Blood* 2006; **107**: 1717-1723 [PMID: 16278306 DOI: 10.1182/blood-2005-06-2529]

56 **Makita S**, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M.CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells.*J Immunol* 2004; **173**: 3119-3130 [PMID: 15322172 DOI: 10.4049/jimmunol.173.5.3119]

57 **Lord JD**, Valliant-Saunders K, Hahn H, Thirlby RC, Ziegler SF.Paradoxically increased FOXP3+ T cells in IBD do not preferentially express the isoform of FOXP3 lacking exon 2.*Dig Dis Sci* 2012; **57**: 2846-2855 [PMID: 22736020 DOI: 10.1007/s10620-012-2292-3]

58 **Saruta M**, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Papadakis KA.Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease.*Clin Immunol* 2007; **125**: 281-290 [PMID: 17897887 DOI: 10.1016/j.clim.2007.08.003]

59 **Yu QT**, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA.Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.*Inflamm Bowel Dis* 2007; **13**: 191-199 [PMID: 17206665 DOI: 10.1002/ibd.20053]

60 **Chen W**, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM.Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.*J Exp Med* 2003; **198**: 1875-1886 [PMID: 14676299 DOI: 10.1084/jem.20030152]

61 **Fantini MC**, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF.Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7.*J Immunol* 2004; **172**: 5149-5153 [PMID: 15100250 DOI: 10.4049/jimmunol.172.9.5149]

62 **Walker MR**, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF.Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.*J Clin Invest* 2003; **112**: 1437-1443 [PMID: 14597769]

63 **Walker MR**, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+. *Proc Natl Acad Sci U S A* 2005; **102**: 4103-4108 [PMID: 15753318]

64 **Allan SE**, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK.Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.*Int Immunol* 2007; **19**: 345-354 [PMID: 17329235 DOI: 10.1093/intimm/dxm014]

65 **Janson PC**, Winerdal ME, Marits P, Thörn M, Ohlsson R, Winqvist O.FOXP3 promoter demethylation reveals the committed Treg population in humans.*PLoS One* 2008; **3**: e1612 [PMID: 18286169 DOI: 10.1371/journal.pone.0001612]

66 **Shevach EM**, Thornton AM.tTregs, pTregs, and iTregs: similarities and differences.*Immunol Rev* 2014; **259**: 88-102 [PMID: 24712461 DOI: 10.1111/imr.12160]

67 **Thornton AM**, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM.Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.*J Immunol* 2010; **184**: 3433-3441 [PMID: 20181882 DOI: 10.4049/jimmunol.0904028]

68 **Lord J**, Chen J, Thirlby RC, Sherwood AM, Carlson CS.T-cell receptor sequencing reveals the clonal diversity and overlap of colonic effector and FOXP3+ T cells in ulcerative colitis. *Inflamm Bowel Dis* 2015; **21**: 19-30 [PMID: 25437819 DOI: 10.1097/MIB.0000000000000242]

69 **Akimova T**, Beier UH, Wang L, Levine MH, Hancock WW.Helios expression is a marker of T cell activation and proliferation.*PLoS One* 2011; **6**: e24226 [PMID: 21918685 DOI: 10.1371/journal.pone.0024226]

70 **Hovhannisyan Z**, Treatman J, Littman DR, Mayer L.Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases.*Gastroenterology* 2011; **140**: 957-965 [PMID: 21147109 DOI: 10.1053/j.gastro.2010.12.002]

71 **Ueno A**, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, Beck PL, Iacucci M, Fort Gasia M, Barkema HW, Panaccione R, Ghosh S.Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients.*Inflamm Bowel Dis* 2013; **19**: 2522-2534 [PMID: 24097227 DOI: 10.1097/MIB.0b013e3182a85709]

72 **Kryczek I**, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J, Chang A, Roliński J, Radwan P, Fang J, Wang G, Zou W.IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.*J Immunol* 2011; **186**: 4388-4395 [PMID: 21357259 DOI: 10.4049/jimmunol.1003251]

73 **Fossiez F**, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S.Interleukin-17.*Int Rev Immunol* 1998; **16**: 541-551 [PMID: 9646176 DOI: 10.3109/08830189809043008]

74 **Annunziato F**, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S.Phenotypic and functional features of human Th17 cells.*J Exp Med* 2007; **204**: 1849-1861 [PMID: 17635957 DOI: 10.1084/jem.20070663]

75 **Cosmi L**, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F.Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor.*J Exp Med* 2008; **205**: 1903-1916 [PMID: 18663128 DOI: 10.1084/jem.20080397]

76 **Harrington LE**, Mangan PR, Weaver CT.Expanding the effector CD4 T-cell repertoire: the Th17 lineage.*Curr Opin Immunol* 2006; **18**: 349-356 [PMID: 16616472 DOI: 10.1016/j.coi.2006.03.017]

77 **Bettelli E**, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.*Nature* 2006; **441**: 235-238 [PMID: 16648838 DOI: 10.1038/nature04753 ]

78 **Kimura A**, Naka T, Kishimoto T.IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.*Proc Natl Acad Sci U S A* 2007; **104**: 12099-12104 [PMID: 17623780 DOI: 10.1073/pnas.0705268104]

79 **Ivanov II**, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR.The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.*Cell* 2006; **126**: 1121-1133 [PMID: 16990136 DOI: 10.1016/j.cell.2006.07.035]

80 **Zhou L**, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR.TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.*Nature* 2008; **453**: 236-240 [PMID: 18368049 DOI: 10.1038/nature06878]

81 **Allan SE**, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK.The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.*J Clin Invest* 2005; **115**: 3276-3284 [PMID: 16211090 DOOI: 10.1172/JCI24685]

82 **Schneider A**, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH.In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.*Sci Transl Med* 2013; **5**: 170ra15 [PMID: 23363979 DOI: 10.1126/scitranslmed.3004970]

83 **Frank DN**, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR.Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.*Proc Natl Acad Sci U S A* 2007; **104**: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104 ]

84 **Manichanh C**, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J.Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.*Gut* 2006; **55**: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]

85 **Sokol H**, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Doré J.Specificities of the fecal microbiota in inflammatory bowel disease.*Inflamm Bowel Dis* 2006; **12**: 106-111 [PMID: 16432374 DOI: 10.1097/01.MIB.0000200323.38139.c6 ]

86 **Conte MP**, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S.Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease.*Gut* 2006; **55**: 1760-1767 [PMID: 16648155]

87 **Izcue A**, Coombes JL, Powrie F.Regulatory lymphocytes and intestinal inflammation.*Annu Rev Immunol* 2009; **27**: 313-338 [PMID: 19302043 DOI: 10.1146/annurev.immunol.021908.132657]

88 **Round JL**, Mazmanian SK.Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.*Proc Natl Acad Sci U S A* 2010; **107**: 12204-12209 [PMID: 20566854 DOI: 10.1073/pnas.0909122107]

89 **Atarashi K**, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K.Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.*Nature* 2013; **500**: 232-236 [PMID: 23842501 DOI: 10.1038/nature12331]

90 **Smith PM**, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS.The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.*Science* 2013; **341**: 569-573 [PMID: 23828891 DOI: 10.1126/science.1241165]

91 **Mucida D**, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H.Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.*Science* 2007; **317**: 256-260 [PMID: 17569825 DOI: 10.1126/science.1145697]

92 **Boschetti G**, Nancey S, Sardi F, Roblin X, Flourié B, Kaiserlian D.Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.*Inflamm Bowel Dis* 2011; **17**: 160-170 [PMID: 20848510 DOI: 10.1002/ibd.21308]

93 **Di Sabatino A**, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, Ubezio C, Massari A, Sampietro GM, Foschi D, Porro GB, Colombo MP, Carsetti R, MacDonald TT, Corazza GR.Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.*Inflamm Bowel Dis* 2010; **16**: 1891-1897 [PMID: 20848485 DOI: 10.1002/ibd.21271]

94 **Li Z**, Arijs I, De Hertogh G, Vermeire S, Noman M, Bullens D, Coorevits L, Sagaert X, Schuit F, Rutgeerts P, Ceuppens JL, Van Assche G.Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.*Inflamm Bowel Dis* 2010; **16**: 1299-1310 [PMID: 20196149 DOI: 10.1002/ibd.21229]

95 **Ricciardelli I**, Lindley KJ, Londei M, Quaratino S.Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.*Immunology* 2008; **125**: 178-183 [PMID: 18422560 DOI: 10.1111/j.1365-2567.2008.02839.x]

96 **Verdonk RC**, Haagsma EB, Jonker MR, Bok LI, Zandvoort JH, Kleibeuker JH, Faber KN, Dijkstra G.Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients.*Inflamm Bowel Dis* 2007; **13**: 703-709 [PMID: 17230494 DOI: 10.1002/ibd.20087]

97 **Taubert R**, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J, Olek S, Falk CS, Manns MP, Jaeckel E.Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies.*J Hepatol* 2014; **61**: 1106-1114 [PMID: 24882050 DOI: 10.1016/j.jhep.2014.05.034]

98 **Kurmaeva E**, Lord JD, Zhang S, Bao JR, Kevil CG, Grisham MB, Ostanin DV.T cell-associated α4β7 but not α4β1 integrin is required for the induction and perpetuation of chronic colitis.*Mucosal Immunol* 2014; **7**: 1354-1365 [PMID: 24717354 DOI: 10.1038/mi.2014.22]

99 **Asseman C**, Fowler S, Powrie F.Control of experimental inflammatory bowel disease by regulatory T cells.*Am J Respir Crit Care Med* 2000; **162**: S185-S189 [PMID: 11029392 DOI: 10.1164/ajrccm.162.supplement\_3.15tac9]

100 **Brunstein CG**, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE.Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.*Blood* 2011; **117**: 1061-1070 [PMID: 20952687 DOI: 10.1182/blood-2010-07-293795]

101 **Di Ianni M**, Falzetti F, Carotti A, Terenzi A, Del Papa B, Perruccio K, Ruggeri L, Sportoletti P, Rosati E, Marconi P, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF.Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation.*Best Pract Res Clin Haematol* 2011; **24**: 459-466 [PMID: 21925099 DOI: 10.1016/j.beha.2011.05.005]

102 **Martelli MF**, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A.HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.*Blood* 2014; **124**: 638-644 [PMID: 24923299 DOI: 10.1182/blood-2014-03-564401]

103 **Kennedy-Nasser AA**, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM.Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.*Clin Cancer Res* 2014; **20**: 2215-2225 [PMID: 24573552 DOI: 10.1158/1078-0432.CCR-13-3205]

104 **Koreth J**, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ.Interleukin-2 and regulatory T cells in graft-*vs*-host disease. *N Engl J Med* 2011; **365**: 2055-2066 [PMID: 22129252]

105 **Matsuoka K**, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-*vs*-host disease.*Sci Transl Med* 2013; **5**: 179ra43 [PMID: 23552371 DOI: 10.1126/scitranslmed.3005265]

106 **Hartemann A**, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D.Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.*Lancet Diabetes Endocrinol* 2013; **1**: 295-305 [PMID: 24622415 DOI: 10.1016/S2213-8587(13)70113-X.]

107 **Long SA**, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ.Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.*Diabetes* 2012; **61**: 2340-2348 [PMID: 22721971 DOI: 10.2337/db12-0049]

108 **Marek-Trzonkowska N**, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz MA, Witkowski P, Mlynarski W, Balcerska A, Mysliwska J, Trzonkowski P.Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children.*Diabetes Care* 2012; **35**: 1817-1820 [PMID: 22723342 DOI: 10.2337/dc12-0038]

109 **Marek-Trzonkowska N**, Myśliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juścińska J, Owczuk R, Szadkowska A, Witkowski P, Młynarski W, Jarosz-Chobot P, Bossowski A, Siebert J, Trzonkowski P.Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets- results of one year follow-up.*Clin Immunol* 2014; **153**: 23-30 [PMID: 24704576 DOI: 10.1016/j.clim.2014.03.016]

110 **Desreumaux P**, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF.Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.*Gastroenterology* 2012; **143**: 1207-17.e1-2 [PMID: 22885333 DOI: 10.1053/j.gastro.2012.07.116]

111 **Schneider A**, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH.The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.*J Immunol* 2008; **181**: 7350-7355 [PMID: 18981158 DOI: 10.4049/jimmunol.181.10.7350]

112 **Bollyky PL**, Lord JD, Masewicz SA, Evanko SP, Buckner JH, Wight TN, Nepom GT.Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells.*J Immunol* 2007; **179**: 744-747 [PMID: 17617562 DOI: 10.4049/jimmunol.179.2.744]

**P-Reviewer:** Miyoshi E **S-Editor:** Yu J **L-Editor:** **E-Editor:**



**Figure 1 FOXP3+ Tregs may mediate their inhibitory function through multiple soluble and cell-surface factors.** CTLA4, TIGIT and PD-1 interact with costimulatory molecules on antigen presenting cells (APC). CD25 binds the T cell growth factor IL-2. CD39 converts local ATP to adenosine. The cytokines IL-10, IL-35 and TGF-β have suppressive functions on nearby immune cells.